For the first time, in 2019, joint guidelines from the European Society of Cardiology and EASD in Guidelines on Diabetes, Prediabetes and Cardiovascular Diseases recommended an SGLT-2 inhibitor (empagliflozin, canagliflozin, and dapagliflozin) or GLP-1 RAs (liraglutide, semaglutide, and dulaglutide) as first-line therapy in patients with newly T2DM with prevalent cardiovascular disease (CVD) or very high/high cardiovascular (CV) risk, such as those with target-organ damage or several CVRFs [70]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.